Sarepta Therapeutics Inc (SRPT) : Sabby Management added new position in Sarepta Therapeutics Inc during the most recent quarter end. The investment management firm now holds 505,937 shares of Sarepta Therapeutics Inc which is valued at $8.7 Million , the company said in a statement filed on May 13, 2016 with the SEC.Sarepta Therapeutics Inc makes up approximately 3.00% of Sabby Management’s portfolio.
Other Hedge Funds, Including , Allianz Asset Management Ag reduced its stake in SRPT by selling 185,405 shares or 69.96% in the most recent quarter. The Hedge Fund company now holds 79,595 shares of SRPT which is valued at $1.4 Million. First Heartland Consultants sold out all of its stake in SRPT during the most recent quarter. The investment firm sold 6,520 shares of SRPT which is valued $112,014.Blackrock Fund Advisors boosted its stake in SRPT in the latest quarter, The investment management firm added 36,371 additional shares and now holds a total of 1,661,818 shares of Sarepta Therapeutics Inc which is valued at $28.6 Million. Sarepta Therapeutics Inc makes up approx 0.01% of Blackrock Fund Advisors’s portfolio.Schwab Charles Investment Management Inc boosted its stake in SRPT in the latest quarter, The investment management firm added 3,105 additional shares and now holds a total of 151,050 shares of Sarepta Therapeutics Inc which is valued at $2.7 Million.
Sarepta Therapeutics Inc opened for trading at $22.15 and hit $23.72 on the upside on Wednesday, eventually ending the session at $23.35, with a gain of 26.63% or 4.91 points. The heightened volatility saw the trading volume jump to 2,13,47,984 shares. Company has a market cap of $1,069 M.
On the company’s financial health, Sarepta Therapeutics Inc reported $-1.15 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 5, 2016. Analyst had a consensus of $-1.14.Analysts expectations of $ .18.During the same quarter in the previous year, the company posted $-1.15 EPS.
Many Wall Street Analysts have commented on Sarepta Therapeutics Inc. Sarepta Therapeutics Inc was Downgraded by Leerink Partners to ” Underperform” on May 3, 2016. Sarepta Therapeutics Inc was Downgraded by Jefferies to ” Underperform” on Apr 29, 2016. Shares were Reiterated by RBC Capital Mkts on Apr 26, 2016 to “Sector Perform” and Lowered the Price Target to $ 5 from a previous price target of $7.50 .
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.